ArticleOncotarget2017
Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- The safety and efficacy of VEGFR tyrosine kinase inhibitors for patients with gliomas: a systematic review, meta-analysis, and a specific analysis on glioblastoma.Neurosurgical review · 2025Pooled it
- SEOM-GEINO clinical guidelines for grade 2 gliomas (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Clinical Impact of MGMT Promoter Methylation in IDH-Mutant Gliomas: Influence of Threshold Selection and Clinical Confounding.Annals of clinical and translational neurology · 2026Article
- Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany.Journal of neuro-oncology · 2025Article
- Clusterin facilitates glioma progression via BCL2L1-dependent regulation of apoptotic resistance.Frontiers in molecular neuroscience · 2025Article
- Prognostic Factors and Resectability Predictors in Insular Gliomas: A Systematic Review.Journal of neurological surgery. Part A, Central European neurosurgery · 2024Article
- T2-FLAIR imaging-based radiomic features for predicting early postoperative recurrence of grade II gliomas.Future oncology (London, England) · 2024Article
- Review
- AInternational journal of molecular sciences · 2023Article
- The Pathological Activation of Microglia Is Modulated by Sexually Dimorphic Pathways.International journal of molecular sciences · 2023Review
- Artificial Intelligence in Brain Tumor Imaging: A Step toward Personalized Medicine.Current oncology (Toronto, Ont.) · 2023Review
- Sex-specific radiomic features of L-[S-methyl-Frontiers in oncology · 2023Article
- Management and outcomes of low-grade gliomas in Africa: A scoping review.Annals of medicine and surgery (2012) · 2022Article
- Identification of Prognostic LncRNAs Subtypes Predicts Prognosis and Immune Microenvironment for Glioma.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Machine Learning and Radiomic Features to Predict Overall Survival Time for Glioblastoma Patients.Journal of personalized medicine · 2021Article
- Promotion of Ros-mediated Bax/Cyt-c apoptosis by polyphyllin II leads to suppress growth and aggression of glioma cells.Translational cancer research · 2021Article
- A review of gliomas-related proteins. Characteristics of potential biomarkers.American journal of cancer research · 2021Review
- DynamicFrontiers in oncology · 2021Article
- A Radiomics Model for Predicting Early Recurrence in Grade II Gliomas Based on Preoperative Multiparametric Magnetic Resonance Imaging.Frontiers in oncology · 2021Article
- Reduction of SCUBE3 by a new marine-derived asterosaponin leads to arrest of glioma cells in G1/S.Oncogenesis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The latest World Health Organization (WHO) classification of tumors of the central nervous system (CNS) integrates both histological and molecular features in the definition of diagnostic entities. This new approach enrolls novel entities of gliomas. In this study, we aimed to reveal the epidemiological characteristics, including age at diagnosis, gender ratio, tumor distribution and survival, of these new entities. We retrospectively reclassified 1210 glioma samples according to the 2016 CNS WHO diagnostic criteria. In our cohort, glioblastoma multiforme (GBM) with wildtype isocitrate dehydrogenase (IDH) was the most common malignant tumor in the brain. Almost all gliomas were more prevalent in males, especially in the cluster of WHO grade III gliomas and IDH-wildtype GBM. Age at diagnosis was directly proportional to tumor grade. With respect to the distribution by histology, we found that gliomas concurrent with IDH-mutant and 1p/19q-codeleted or with single IDH-mutant were mainly distributed in frontal lobe, while those with IDH-wildtype were dominant in temporal lobe. Lesions located in insular lobe were more likely to be IDH-mutant astrocytoma. In summary, our results elucidated the epidemiological characteristics as well as the regional constituents of these new gliomas entities, which could bring insights into tumorigenesis and personalized treatment of Chinese glioma population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.